Skip to main content
Clinical Trials/NCT06249503
NCT06249503
Completed
Phase 4

Ultrasound Guided Activated and Non-activated Platelet Rich Plasma Injection Versus Hydro Dissection for Treatment of Carpal Tunnel Syndrome

Ain Shams University1 site in 1 country90 target enrollmentFebruary 1, 2023

Overview

Phase
Phase 4
Intervention
platelet rich plasma
Conditions
Carpal Tunnel Syndrome
Sponsor
Ain Shams University
Enrollment
90
Locations
1
Primary Endpoint
Pain visual analogue scale
Status
Completed
Last Updated
last year

Overview

Brief Summary

PRP represents a promising, nonsurgical option for patients with carpal tunnel syndrome (CTS) with improvement in symptoms compared to placebo, conservative treatment, and local corticosteroid injections at 3-months postintervention. However, the lack of significant long-term results in pain and function demands the presence of future studies to further determine the long-term effect on a large group of homogeneous patients. More over to determine the clinical indications, effect on differing CTS severities, and the effects of preparation, concentration of the platelets and methods of activation of PRP

Detailed Description

1. The patients are blinded to the type of drug and the researchers are blinded to the randomization. Randomization will be done using a research randomization program (http://www.randomizer.org) 2. Patients will be randomly divided into three groups; each consists of 30 patients. Group 1 will include patients subjected to ultrasound guided activated PRP injection, group 2 will include patients subjected to ultrasound guided non-activated PRP injection, and group 3 patients will be subjected to ultrasound guided hydro dissection using a combination of steroid (Triamcinolone 40mg), LA (local anesthesia) and dextrose.

Registry
clinicaltrials.gov
Start Date
February 1, 2023
End Date
September 1, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with mild to moderate idiopathic Carpal Tunnel Syndrome with clinical manifestations, diagnosed by electrophysiological study and ultrasound. CTS grading will be performed on basis of an electrophysiological study following Stevens classification (Stevens; 1997).
  • Early CTS: abnormal findings only in both comparative studies (≥0.5ms difference in peak latency)
  • Mild CTS: abnormal median sensory study (peak latency ≥3.5ms)
  • Moderate CTS: abnormal median sensory study and prolonged median distal motor latency (onset latency ≥4.5ms)
  • Sever CTS: any of the above mentioned abnormalities together with the evidence of axonal loss either by absent median sensory response, low amplitude, or absent median motor response (\<2µV)

Exclusion Criteria

  • • Patients suffering from diabetes, hypothyroidism, rheumatoid arthritis, , cervical radiculopathy, polyneuropathy, brachial plexopathy, traumatic nerve injury, thoracic outlet syndrome, coagulopathy
  • Pregnancy
  • Previous corticosteroid injection into the carpal tunnel.
  • Previous carpal tunnel decompressive surgery.

Arms & Interventions

Activated PRP

PRP is activated by adding 200μl of 0.025 calcium chloride and used in hydrodissection.

Intervention: platelet rich plasma

Non-Activated PRP

PRP is used directly in hydrodissection.

Intervention: platelet rich plasma

Steroid group

Hydro dissection using a combination of steroid (Triamcinolone 40mg), local anesthetics and dextrose.

Intervention: platelet rich plasma

Outcomes

Primary Outcomes

Pain visual analogue scale

Time Frame: 2 weeks,1,3 and 6 months

Ruler with number on it and the scale by measuring the distance in millimeter from 0 to 10 where is 0 means no pain and 10 means sever disabling pain and in between the different degrees of pain

Secondary Outcomes

  • Boston Carpal Tunnel Syndrome Questionnaire(2 weeks, 1,3 and 6 months)

Study Sites (1)

Loading locations...

Similar Trials